MediciNova, Inc. (MNOV)
1.45
-0.02
(-1.36%)
USD |
NASDAQ |
Oct 15, 16:00
1.46
+0.01
(+0.69%)
After-Hours: 20:00
MediciNova Research and Development Expense (Quarterly) : 1.024M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.024M |
| March 31, 2026 | 1.258M |
| December 31, 2025 | 1.539M |
| September 30, 2025 | 1.536M |
| June 30, 2025 | 2.184M |
| March 31, 2025 | 1.835M |
| December 31, 2024 | 1.902M |
| September 30, 2024 | 1.854M |
| June 30, 2024 | 1.641M |
| March 31, 2024 | 1.776M |
| December 31, 2023 | 1.645M |
| September 30, 2023 | 0.789M |
| June 30, 2023 | 1.682M |
| March 31, 2023 | 1.423M |
| December 31, 2022 | 1.965M |
| September 30, 2022 | 2.40M |
| June 30, 2022 | 2.504M |
| March 31, 2022 | 2.062M |
| December 31, 2021 | 1.771M |
| September 30, 2021 | 2.081M |
| June 30, 2021 | 2.521M |
| March 31, 2021 | 2.139M |
| December 31, 2020 | 1.791M |
| September 30, 2020 | 2.233M |
| June 30, 2020 | 2.194M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.246M |
| December 31, 2019 | 1.823M |
| September 30, 2019 | 1.145M |
| June 30, 2019 | 1.466M |
| March 31, 2019 | 1.634M |
| December 31, 2018 | 0.2145M |
| September 30, 2018 | 2.37M |
| June 30, 2018 | 1.380M |
| March 31, 2018 | 1.662M |
| December 31, 2017 | 1.158M |
| September 30, 2017 | 1.268M |
| June 30, 2017 | 0.8972M |
| March 31, 2017 | 0.9007M |
| December 31, 2016 | 0.5916M |
| September 30, 2016 | 0.8896M |
| June 30, 2016 | 0.9627M |
| March 31, 2016 | 1.075M |
| December 31, 2015 | 0.9138M |
| September 30, 2015 | 0.5867M |
| June 30, 2015 | 0.797M |
| March 31, 2015 | 0.7197M |
| December 31, 2014 | 0.7829M |
| September 30, 2014 | 0.8933M |
| June 30, 2014 | 0.8356M |
| March 31, 2014 | 0.7479M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Viking Therapeutics, Inc. | 115.75M |
| IDEAYA Biosciences, Inc. | 108.69M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |